Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2021-04-12 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
中信证券关于公司2020年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the 2020 internal control self-evaluation report of Xiamen Aide Biomedical Technology Co., Ltd. It includes extensive discussion of the company's internal control environment, principles, systems, activities, and evaluation standards. The document references regulatory requirements and internal control standards, and it provides an auditor's or sponsor's opinion on the internal control report. It is not the internal control report itself but rather a verification or audit opinion on that report. This type of document fits best under Audit Report / Information (AR), as it is a standalone audit-related report focusing on internal control evaluation and verification, not a full annual report or other category. The document length and content confirm it is a substantive report, not a brief announcement or certification letter, so it is not RPA or RNS. Therefore, the classification is AR with high confidence. FY 2020
2021-04-12 Chinese
独立董事述职报告（周雪林）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of the company, summarizing their duties, attendance at meetings, opinions on various company matters, committee work, inspections, investor protection efforts, and training during the 2020 fiscal year. It is a comprehensive narrative about the director's activities and responsibilities over the year, not a brief announcement or a certification. The content focuses on governance and oversight activities rather than financial results or audit opinions alone. This fits best under Board/Management Information (MANG), which covers announcements related to board members and senior management activities and reports. The document length is 2608 characters, which is sufficient for a detailed report but not a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2021-04-12 Chinese
独立董事关于相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on various matters related to the company's 2020 annual report and related issues. It references the 2020 annual report, internal control self-evaluation, profit distribution plan, audit firm appointment for 2021, and other governance and compliance matters. The document is a formal opinion letter from independent directors, providing their independent judgment on these issues, rather than the annual report itself. The length is 2635 characters, which is relatively short and consistent with an opinion or certification document rather than a full annual report. It does not contain full financial statements or detailed financial performance data. Therefore, it is not the Annual Report (10-K) itself but an independent opinion related to the annual report and governance matters. This type of document fits best under Regulatory Filings (RNS), as it is a regulatory disclosure related to governance and compliance but not a full report or announcement of voting results or remuneration details.
2021-04-12 Chinese
关于与海和药物达成靶向药物临床研究合作的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a cooperation agreement between the company and another pharmaceutical company for clinical research collaboration. It details the nature of the agreement, the parties involved, and the expected impact on the company. There are no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. The document is a corporate announcement about a business collaboration, not a financial report, audit, or management change. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing or legal proceeding update. The best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement about a material cooperation agreement that does not fall into more specific categories.
2021-03-12 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (687 characters) from a company about obtaining an invention patent certificate issued by the Chinese National Intellectual Property Administration. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, and no meeting or voting information. It is a corporate announcement about intellectual property rights, not a financial report or regulatory filing. Given the content and length, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about patent acquisition, which is best classified under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2021-02-22 Chinese
关于公司完成工商变更登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of business registration changes and the issuance of a new business license. It details changes in registered capital due to share repurchases and adjustments following shareholder meetings. The document does not contain financial statements, detailed financial performance data, or management analysis. It is a formal public notice about corporate registration and capital changes, not a full financial report or earnings release. The document length is short (1373 characters), and it serves as an official announcement of corporate changes rather than a report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-02-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.